Latex allergy: a model for therapy.

Area of Science:

• Immunology
• Allergology
• Materials Science

Background:

• Natural rubber latex allergy emerged significantly with increased latex glove use in the 1980s.
• High-risk groups include healthcare workers, spina bifida patients, and individuals with fruit/vegetable allergies due to cross-reactivity.
• Advances in allergen characterization positioned latex allergy as a model for therapeutic development.

Purpose of the Study:

• To review the evolution, current status, and future therapeutic strategies for natural rubber latex allergy.
• To highlight the need for improved manufacturing and novel treatments in light of changing global demographics.
• To explore the potential of immunotherapy and hypoallergenic latex preparations.

Main Methods:

• Review of epidemiological studies and allergen identification research.
• Analysis of current and experimental immunotherapy approaches (subcutaneous, sublingual).
• Investigation into the development of hypoallergenic latex derivatives and vaccine strategies.

Main Results:

• Allergen identification, epitope mapping, and recombinant allergen production have improved diagnostics.
• Subcutaneous and sublingual immunotherapies show efficacy but carry high risks of adverse events.
• Hypoallergenic latex preparations, modified allergen molecules, and T cell epitope peptides are promising therapeutic avenues.

Conclusions:

• Despite reduced exposure in Western countries, latex allergy remains a global health challenge, necessitating improved manufacturing and novel treatments.
• Effective, safe immunotherapy and vaccines are crucial for high-risk individuals, with modified allergens and epitope peptides showing potential.
• Further research into hypoallergenic materials and specific immunotherapy regimens is vital for managing latex allergy.